全球鮑氏不動桿菌肺炎治療藥物市場：依藥物類別、給藥途徑及地區分類

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, By Route of Administration, By Geography

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年全球鮑氏不動桿菌肺炎治療市場規模預計為7.686億美元，預計2033年將達到11.557億美元。預計2026年至2033年，該市場將以6.0%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	7.686億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.00%	2033年市場規模預測：	11.557億美元

鮑氏不動桿菌肺炎是由鮑氏不動桿菌屬細菌引起的一種嚴重肺炎。這類細菌廣泛存在於土壤和水中。近年來，由多重抗藥性鮑曼不動鮑氏不動桿菌菌株引起的院內獲得性肺炎病例數量急劇增加。此病通常影響免疫功能低下的患者以及在加護病房接受人工呼吸器的患者。抗菌藥物抗藥性是鮑曼鮑氏不動桿菌肺炎治療的主要挑戰。迫切需要針對該病原體的新療法。

市場動態：

全球鮑氏不動桿菌肺炎治療市場受抗藥性菌株日益普遍以及醫院獲得性肺炎和人工呼吸器相關性肺炎發病率上升的驅動。根據美國疾病管制與預防中心 (CDC) 統計，鮑曼不動鮑氏不動桿菌感染疾病占美國每年所有醫院獲得性肺炎病例的 8% 至 10%。此外，抗生素開發平臺有限以及缺乏專門針對鮑氏不動桿菌肺炎的已通過核准療法也帶來了市場機會。然而，高昂的研發成本和新藥認證相關的監管障礙阻礙了市場成長。多重抗藥性細菌的日益普遍、診斷技術的進步以及對有效療法的需求等因素都對市場產生影響。製藥公司、研究機構和醫療服務提供者之間的合作在推動治療方法的研發中發揮著至關重要的作用。

本研究的主要特點：

本報告對全球鮑氏不動桿菌肺炎治療市場進行了詳細分析，提出了 2026 年至 2033 年預測期內的市場規模和複合年成長率 (CAGR%)，其中 2025 年為基準年。
此外，它還指出了每個細分市場的潛在收入成長機會，並說明了該市場中一個有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本報告根據以下參數介紹了全球鮑氏不動桿菌肺炎治療市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
這份「全球鮑氏不動桿菌肺炎治療市場」報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球鮑氏不動桿菌肺炎治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc（GSK）
AstraZeneca plc
Novartis AG
Johnson & Johnson
Sanofi SA
Bayer AG
Basilea Pharmaceutica

第8章

調查方法
關於本公司

簡介目錄

Product Code: CMI6566

Global Acinetobacter Pneumonia Therapeutics Market is estimated to be valued at USD 768.6 Mn in 2026 and is expected to reach USD 1,155.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 768.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.00%	2033 Value Projection:	USD 1,155.7 Mn

Acinetobacter pneumonia is a severe type of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are commonly found in soil and water. In recent times, there has been a steep rise in the number of cases of hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter strains. Typically, it affects immunocompromised patients or those on mechanical ventilation in intensive care units. Antibiotic resistance has emerged as a major challenge in treating Acinetobacter pneumonia. Novel therapeutic approaches targeting this pathogen are the need of the hour.

Market Dynamics:

The global Acinetobacter pneumonia therapeutics market is driven by the growing prevalence of drug-resistant strains and increasing incidence of hospital-acquired or ventilator-associated pneumonia. According to the Centers for Disease Control and Prevention, Acinetobacter infections account for 8-10% of all hospital-acquired pneumonia cases in the U.S. every year. Moreover, the restricted antibacterial pipeline and lack of approved therapies specific to Acinetobacter pneumonia act as opportunities in the market. However, high development costs and regulatory hurdles associated with new drug approvals hamper the market growth. The market is influenced by factors such as increasing incidence of multidrug-resistant strains, advancements in diagnostic technologies, and the need for effective treatment options. Collaborations between pharmaceutical companies, research institutions, and healthcare providers play a crucial role in advancing therapeutic solutions.

Key Features of the Study:

This report provides an in-depth analysis of the global acinetobacter pneumonia therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2026-2033, considering 2025 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acinetobacter pneumonia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutica
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global acinetobacter pneumonia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acinetobacter pneumonia therapeutics market.

Detailed Segmentation:

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Cephalosporins
Carbapenems
Aminoglycosides
Polymyxins
Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Intravenous
Others
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Global Acinetobacter Pneumonia Therapeutics Market, Key Players
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc (GSK)
AstraZeneca plc
Novartis AG
Johnson & Johnson
Sanofi S.A.
Bayer AG
Basilea Pharmaceutica

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Global Acinetobacter Pneumonia Therapeutics Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rising prevalence of Acinetobacter pneumonia infections
- Increasing research & development activities
- Growing healthcare expenditure
Impact Analysis
Key Highlights
Regulatory Scenario
Service offering Portfolio
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Pipeline Analysis

4. Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Cephalosporins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Carbapenems
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Polymyxins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

5. Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Acinetobacter Pneumonia Therapeutics Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 - 2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021 - 2033,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline plc (GSK)
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Basilea Pharmaceutica
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views